• Clinical science

COVID-19 (coronavirus disease 2019)

Summary

COVID-19 is an acute infectious respiratory disease caused by infection with the coronavirus subtype SARS-CoV-2, first detected in Wuhan, China, in December 2019. It is currently spreading worldwide and is considered a pandemic disease. Transmission occurs primarily via respiratory droplets (sneezing and coughing). Following an incubation period of 2–14 days (average ∼ 5 days), COVID-19 usually presents with fever and upper respiratory symptoms, especially dry cough and often dyspnea; asymptomatic courses and certain other symptoms can also occur. Clinical courses range from very mild to developing into severe with pneumonia and even critical with life-threatening complications such as ARDS, aseptic shock, and organ dysfunction. Recommendations for infection control and preventive measures vary according to the appropriate health department/agency, but generally involve personal hygiene (e.g., washing hands), avoiding exposure/public places, quarantines/isolation, and wearing suitable personal protective equipment (PPE). Diagnosis is confirmed by RT-PCR of SARS-CoV-2 DNA isolated from patient specimens, preferably from at least a nasopharyngeal swab. In some cases of mild symptoms and depending on local recommendations, diagnostic testing may not be warranted. In mild clinical courses, patients should self-isolate with supportive care and monitoring at home. Patients with clinical manifestations of severe courses (i.e., dyspnea, cyanosis, chest discomfort, or mental status change), signs of respiratory distress (SpO2 ≤ 93%, respiratory rate > 22/min), or possibly at high-risk for severe course (≥ 65 years or certain underlying conditions) should be admitted. Hospitalized patients should receive supportive and oxygen therapy while being regularly monitored with supporting laboratory and imaging studies (Chest x-ray, Chest CT, possibly POCUS). Notable findings indicative of progression to pneumonia include lymphocytopenia, elevated CRP, and CT scans showing ground-glass opacities (can progress to solid white consolidation in severe infection) and inter- and/or intralobular septal thickening (indicating swelling of the interstitial space). POCUS can assist in monitoring of pneumonia and possibly screening for cardiomyopathy. Intensive care and airway management are indicated for patients displaying signs of respiratory failure (e.g., dyspnea with hypoxemia, respiratory rate > 30/min). Endotracheal intubation should be initiated early, preferably by rapid-sequence induction and avoid virus aerosol-generating procedures (AGPs), such as noninvasive ventilation, high-flow oxygen therapy, bronchoscopy, and nebulizer treatment, whenever feasible. Mechanical ventilation should consist of lower tidal volumes and PEEP and FiO2 settings in line with ARDS protocols (e.g., ARDSnet protocol). There is currently no effective treatment; any antiviral treatments should only be considered case-by-case as part of research studies and compassionate use programs. The overall mortality rate ranges from ∼ 0.5–3%, and greatly increases for elderly (∼ 15% for > 80 years) as well as those with certain underlying conditions (e.g., cardiac, pulmonary, diabetes mellitus).

Given the severity of the situation, we at AMBOSS are doing our best to accurately update and expand the content as quickly as possible. Considering that information about COVID-19 is changing daily, we greatly appreciate your understanding of potential delays and hiccups during our development process.

Additional free AMBOSS resources for COVID-19

In addition to this learning card, the AMBOSS team offers further learning cards in the library that are relevant for the management of severe COVID-19. Access to the following learning cards is possible without a paid AMBOSS subscription:

References:[1][2]

Epidemiology

  • The disease is currently spreading worldwide. Refer to the Johns Hopkins University & Medicine Coronavirus Resource Center (https://coronavirus.jhu.edu/map.html) for up-to-date statistics. [3]
  • To date, the greatest number of confirmed cases has been reported from the US, mainland China, Italy, and Spain. The greatest number of deaths have been reported from Italy, Spain, and China.
  • WHO declared the COVID-19 outbreak a Public Health Emergency of International Concern on January 30, 2020.
  • WHO classified the disease as a pandemic on March 11, 2020.
  • Men and women are equally affected. [4]
  • The median age of patients is ∼ 47 years in China. [5]
  • Mortality rate ranges from ∼ 0.5 to 3%.
  • The mortality rate greatly increases > 60 years of age, with the most lethal rates for individuals > 80 years reaching ∼ 15%. [4]

Pathophysiology

  • The virus
    • SARS-CoV-2 is a potentially lethal type of coronavirus, a subfamily of enveloped nonsegmented positive-sense RNA viruses that usually cause mild respiratory tract infections.
    • Specifically, it is a β-coronavirus. The other two β-coronaviruses were SARS-CoV and MERS-CoV, which both also caused outbreaks of potentially fatal respiratory tract infections in 2003 and 2012, respectively. [6]
    • Genome sequencing shows 96.2% identity to a bat coronavirus RaTG13, making bats the most likely natural host of the SARS-CoV-2 origin. [7]
      • The initial animal-to-human transmission likely occurred via direct exposure to an unknown intermediate host at the Huanan Seafood Wholesale Market in Wuhan, China, a live animal and seafood market (“wet market”) that was identified as the point of origin. [8]
    • A population genetic analysis conducted in January 2020 concluded there are two prevalent genotypes of SARS-CoV-2, an L-type (∼ 70%) and an S-type (∼ 30%), with very minor differences. [9]
      • The authors suggested:
        • S-type was the original type transmitted to humans from the animal host and is less contagious and aggressive.
        • L-type evolved from the S-type and is somewhat more contagious and aggressive.
      • However, the WHO currently does not believe the genetic diversity observed in the study means that virus activity is changing. [10]
      • Because of limited data, more research is needed to better understand the implications of genetic diversity on virulence and lethality.
  • Invasion of host cells [11]
    • Entry point: ACE2, which catalyzes the conversion of angiotensin II, is expressed in the surface epithelium of the lungs and other organs. ACE2 receptors have been identified as the binding site for SARS-CoV-2 in animals and humans. [12][13][14][15][16]
    • Transmembrane protease, serine 2 (TMPRSS2): The virus uses TMPRSS2 to invade host cells. It then fuses with the membrane and enters the cell via endosomes.
  • Replication cycle:
    • Enzymes, such as RNA polymerase or proteases, that are virally induced by endosomal viral RNA release replicate viral components.
    • Endosomes with newly constituted viruses are released via exocytosis.
  • Direct cytopathic effects
    • Virus-induced damage, particularly to the alveolar epithelium
    • Other organs, especially the liver and heart, can also be affected.
  • Dysregulated immune response: As in sepsis, there is an immune response involving the release of cytokines (IL-6) and the triggering of an acute inflammatory response. However, COVID-19 usually does not lead to hypotension, a defining feature of septic shock.

There are currently many hypotheses founded on the research conducted on previous coronavirus outbreaks (MERS, SARS); the viability of these hypotheses and the application of past research to the present situation has yet to be determined!

Initial infection

  • Transmission: person-to-person, primarily via respiratory droplets (sneezing and coughing)
    • Direct contact transmission: especially hand-to-face contact
    • Fomite transmission: not documented but conceivably possible, especially with objects and surfaces that may have recently come into contact with infected individuals
      • Transmission via mail and packaged (imported) goods: There is no evidence to suggest that mail and packaged (imported) goods pose a risk for the spread of COVID-19.
    • Fecal-oral transmission: Evidence that both SARS-CoV and MERS-CoV are excreted fecally suggests that fecal-oral transmission is possible. [17]
  • Incubation period: 2–14 days, usually ∼ 5 days [18][19]

The transmission of SARS-CoV-2 by asymptomatic individuals can occur, but individuals are most contagious when they are symptomatic.

Clinical features

  • Symptoms
  • Course: The disease has a wide spectrum of severity, ranging from mild to critical.

Differential diagnoses

COVID-19 Influenza Common cold Allergic rhinitis
Fever +++ +++ - -
Cough +++ +++ +++ ++
Fatigue +++ +++ + -
Anorexia ++ ++ - -
Dyspnea ++ - - -
Myalgia ++ +++ + -
Rhinitis + + +++ +++
Sneezing - - +++ +++
Sore throat + + +++ -
Diarrhea + + - -
Headache - +++ ++ -
Itchy eyes - - - +++

+++ = very common, ++ = common, + = less common, - = rare

Infection control and preventive measures

  • Health care facilities should take hygiene and isolation measures in accordance with state or local health department recommendations and regulations. [23]
  • Health care providers should emphasize the following when counseling concerned patients:
    • Hand hygiene:
      • Hands should be washed with soap and water or disinfected with a virucidal hand disinfectant after contact with potentially virus-contaminated objects and infected persons
      • Avoid touching the face: i.e., the eyes, nose, and mouth.
    • Respiratory hygiene and cough etiquette
      • Avoid coughing or sneezing in the direction of others!
      • Use tissues and discard these after use.
        • If tissues are unavailable, coughing and sneezing into the crook of the arm can help keep hands free of contamination.
      • Maintain 3–6 ft (at least an arm's length) distance to coughing or sneezing persons.
    • Avoid exposure
      • Avoid crowds of people (public transport, train stations, airports, mass events).
      • Avoid travel to areas of outbreak.
    • Masks
      • In PUIs and individuals with confirmed infection: useful for preventing the diffusion of respiratory secretions, e.g., during patient transports
      • In health care facilities or home care settings: crucial for health workers and persons taking care of an infected individual in close settings (in a health care facility or at home)
        • Surgical masks do not provide adequate protection in the setting of invasive diagnostics or those at high risk of exposure.
          • N95 respirators and protective eyewear are recommended for healthcare personnel that are potentially exposed to airborne and fluid hazards (e.g., during invasive procedures). [24]
          • Confirmed COVID-19 patients and PUIs can use standard N95 respirators.
          • If surgical N95 respirator bottlenecks occur, unvalved N95 respirators may be used with a face shield.
          • Respirators and masks should be used resourcefully with special consideration for health facility needs.
      • In the general population: Surgical masks are most likely ineffective and may even pose an additional risk of infection.

The CDC has recommended that organizers cancel or postpone in-person events with ≥ 50 people in the US for the next 8 weeks.

Evaluation and testing

Real-time polymerase chain reaction (RT-PCR) of DNA collected from patient specimens is conducted to confirm infection with SARS-CoV-2. It is important to follow health department policies for collecting clinical specimens to minimize the risk of spreading infection and ensure quick and accurate test results.

Initial medical evaluation

  • Calling ahead
    • Individuals with mild COVID-19 symptoms and/or exposure to the virus who think they should be medically evaluated for COVID-19 should first call their healthcare facility (HCF) before visiting to determine if there are special directions (e.g., visit a specific site for testing).
    • If emergency medical services (EMS) are required (COVID-19 related or not), EMS should be notified if the individual is at risk of having COVID-19.
  • Recommendations for COVID-19 testing: vary according to health departments
    • Guiding factors consider epidemiological data and availability of diagnostic testing resources and health care personnel.
    • The CDC states that not everyone needs testing for COVID-19, and defers decisions about testing to respective health departments and/or individual clinicians. [25]
      • Exception: Older adults or individuals with certain underlying conditions, including cardiovascular, pulmonary, renal, or metabolic (diabetes mellitus) conditions should seek medical care for testing as soon as symptoms begin.
    • In general, clinicians are urged to make judgment calls if a patient's signs, symptoms, and risk factors warrant COVID-19 testing.
    • In some cases (e.g., if testing is limited), predetermined priorities should be considered to maximize the benefits of testing. The CDC has set priorities for testing, consisting of: [26]
      • Priority 1: Ensure optimal care options for all hospitalized patients, lessen the risk of nosocomial infections, and maintain the integrity of the healthcare system
        • Hospitalized patients
        • Symptomatic healthcare workers
      • Priority 2: Ensure that those who are at highest risk of complication of infection are rapidly identified and appropriately triaged
        • Patients in long-term care facilities with symptoms
        • Patients 65 years of age and older with symptoms
        • Patients with underlying conditions with symptoms
        • First responders with symptoms
      • Priority 3: As resources allow, test individuals in the surrounding community of rapidly increasing hospital cases to decrease community spread, and ensure health of essential workers
        • Critical infrastructure workers with symptoms
        • Individuals who do not meet any of the above categories with symptoms
        • Health care workers and first responders
        • Individuals with mild symptoms in communities experiencing high COVID-19 hospitalizations
      • Non-priority: Individuals without symptoms
    • Some health agencies and departments (e.g., in the United Kingdom) directly recommend that individuals suspected of COVID-19 not be tested for the virus if they only have mild symptoms and instead, should remain at home in isolation. [27]
  • Notify authorities: All measures should be consistent with appropriate health department regulations. In the US, health care personnel should immediately notify state or local health departments of patients with fever and/or respiratory symptoms suspected of COVID-19 (i.e., person under investigation, or PUI) to determine:
    • If criteria are met for testing
    • To receive support in collecting, storing, and shipping specimens

Collecting and handling clinical specimens (recommendations based upon CDC guidelines) [28]

  • General measures
    • Specimens should be collected at a clinical or public health laboratory for routine testing of respiratory pathogens.
    • Testing should only be conducted for individuals demonstrating symptomatic disease in consultation with a clinician.
    • Close contact with PUIs should be avoided; anytime it is required, health care personnel should wear all recommended personal protective equipment (PPE) for COVID-19.
  • Collection of specimens
    • For all individuals, conduct on an upper respiratory specimen.
      • Preferred method by the CDC: nasopharyngeal specimen (NPS) using a single synthetic fiber swab with a plastic shaft that is gently inserted through the nostril to the posterior nasopharynx , where it is left for several seconds to absorb secretions before slowly removing while rotating
      • Alternative methods
        • Oropharyngeal (OP) swab (throat swab): swab the posterior pharynx while avoiding the tongue
        • Nasal mid-turbinate (NMT) swab
        • Anterior nares specimen (NS)
        • Possibly nasopharyngeal wash/aspirate or nasal aspirate
      • Handling
        • Swabs should be placed immediately into sterile transport tubes containing 2–3 ml of viral transport media
        • If both NP and OP swabs: combine in a single tube
    • When feasible, lower respiratory tract specimens should also be collected.
      • If productive coughing: from sputum
        • After rinsing the mouth with water, the patient should spit deep cough sputum into a sterile sputum collection cup or sterile dry container.
      • If undergoing mechanical breathing: lower respiratory tract aspirate or bronchoalveolar lavage
        • 2–3 mL should be placed in a sterile sputum collection cup or sterile dry container.
    • Many locations have necessary materials already prepared in respiratory virus swab collection kits.
  • Storage and transport of specimens
    • Store specimens at 2–8°C up to 72 hours after collection.
      • If there is a delay in shipping or testing, specimens should be stored at -70°C.
    • Label and transport immediately as requested by the appropriate government health agency/departments.
    • In the US, the CDC requests the following:
      • Label each specimen container with the patient’s ID number (e.g., medical record number), unique specimen ID (e.g., laboratory requisition number), specimen type (e.g., serum) and the date the sample was collected.
      • Complete a CDC Form 50.34 for each specimen submitted. In the upper left box of the form,
        1. for test requested select “Respiratory virus molecular detection (non-influenza) CDC-10401” and
        2. for At CDC, bring to the attention of enter “Stephen Lindstrom: 2019-nCoV PUI”.
      • Ship overnight to CDC on ice pack.

For patients in late, severe stages of infection (pneumonia, ARDS, sepsis), swab specimens from the upper respiratory tract may be negative, while the lower respiratory tract is positive.

Laboratory testing

  • Real-time polymerase chain reaction (RT-PCR): confirms infection with SARS-CoV-2 from patient specimens
    • Results should be available within a few hours
    • Has both high sensitivity and specificity
    • Sensitivity likely increases when testing specimens from multiple sites. [29]

A PCR can initially be negative. In such cases, if there is still concern that a patient is infected, repeating PCR testing every 2–3 days should be considered, potentially with both upper and lower respiratory tract specimens.

Management

For any management steps involving close contact with patients with confirmed or suspected COVID-19, observe all hygiene and isolation measures in accordance with state or local health department recommendations and regulations! (See “Infection prevention and control in healthcare settings” and “PPE for COVID-19” above.) [23]

Reporting

  • All measures should be consistent with state or local health department regulations. Generally, this involves notifying state and/or local health departments as well as healthcare facility (HCF) infection control personnel of persons under investigation (PUI) and confirmed cases. [30]

Initial steps and site of care

  • Measure vital signs (BT, BP, HR, RR) and SpO2
  • Consider ambulant management with watchful waiting for patients with:
    • Low fever (< 100.4°F or 38.3°C)
    • No signs of respiratory distress
    • Normal SpO2
    • Negative qSOFA score
  • Admit symptomatic patients with the following signs:
    • Difficulty breathing
    • Persistent pain or pressure in the chest
    • Change in mental status (e.g., confused, nonresponsive)
    • Signs of cyanosis (e.g., bluish lips)
    • SpO2 ≤ 93%
    • Respiratory rate > 22/min
    • Fever > 37.5°C
    • Systolic BP: ≤ 100 mmHg
  • Depending on clinical status, consider admitting high-risk patients who show any COVID-19 symptoms to closely monitor for developing a severe course and complications. Individuals considered at high-risk for a severe course (and thus a higher mortality rate) include those with: [31]
  • Especially for hospitalized patients, obtain patient preferences for the following:

Management of asymptomatic or mild courses

There is no effective antiviral treatment; management consists of supportive self-care at home (home care) and isolation in accordance with health department regulations.

  • Minimize spread of infection: [32]
    • Stay in a designated “sick room” away from other people.
    • Use a separate bathroom if possible.
    • Do not leave home except to get medical care.
    • If an individual must go out, avoid public places, public transportation, ridesharing, and taxis.
    • Call before seeking medical care.
    • Wear a facemask.
    • Follow general protective measures as described above.
    • Avoid sharing personal household items and wash any used items thoroughly.
    • Clean “high-touch” surfaced daily.
  • Management of close contacts: notifiable in accordance with state or local health department regulations
  • Supportive care: Get rest and stay hydrated.
  • Fever management: Antipyretic therapy for controlling fever in patients with COVID-19 is usually not necessary.
    • When to consider antipyretic therapy:
      • High-grade fever (e.g., > 39.4°C/103°F)
      • Increased risk of dehydration or circulatory dysregulation
    • Agents: both paracetamol and NSAIDS are safe options (despite controversy; see “Do ACE inhibitors and NSAIDs aggravate COVID-19?” for more information)
      • Acetaminophen (paracetamol): Drug of choice in most patients, unless contraindications are present (e.g., liver disease)
      • Alternative: Ibuprofen or other NSAIDS, but limit use in elderly patients and those with cardiovascular or renal disease.
  • Monitor symptoms carefully: Individuals should seek medical care immediately if symptoms worsen or any emergency warning signs develop, including: [25]
    • Difficulty breathing
    • Persistent pain or pressure in the chest
    • Change in mental status (e.g., confused, nonresponsive)
    • Signs of cyanosis (e.g., bluish lips)
  • Discontinuing home isolation: Determining when to end home isolation is approached from different strategies, which can vary according to health departments and testing resources. See “Discontinuation of transmission-based precautions” below.

Management of hospitalized patients

  • Administer O2 therapy via nasal canula: 1–6 L O2/min if SpO2 ≤ 93%
    • Careful with patients with COPD: a SpO2 of 90–93% is appropriate
  • Evaluation and monitoring: Vital signs, SpO2, laboratory studies, and imaging should regularly be conducted to help guide management and monitor progression. The following studies should be considered:

Laboratory studies [20]

Regular laboratory monitoring of hospitalized patients should include: ABG/VBG, CBC, electrolyte panel, inflammatory markers (CRP, LDH, procalcitonin), organ function (creatinine, urea nitrogen, urine volume, LFTs, cardiac enzymes), coagulation tests, and D-dimer. Blood culture should also initially be considered.

Imaging [34][20]

All hospitalized patients should undergo initial and follow-up imaging according to the clinical course.

  • Chest x-ray: usually bilateral, peripheral opacities in multiple lobes [35][36]
  • Point-of-care ultrasound (POCUS): better results than chest x-ray and easily repeatable for reevaluation [37]
    • Thickened and irregular pleural lines
    • B lines as an early sign indicate a need for intensifying care
    • Consolidation (both non-translobar or translobar) indicates progression of the pulmonary disease
    • Should also screen for cardiomyopathy
  • Chest CT: recommended for hospitalized patients [34][38][39]
    • Can initially be normal in up to 60% of hospitalized patients [39]
    • CT findings are sometimes already present before clinical manifestation.
    • Findings: generally bilateral, but a minority are unilateral
      • Ground glass opacities that can progress to solid white consolidation in severe infection
      • Inter- and/or intralobular septal thickening
      • Mixed “crazy-paving” pattern = combination of ground-glass opacity with superimposed interlobular septal thickening and/or intralobular septal thickening

Intensive care

  • Indications: Admit to ICU and initiate intubation if any of the following are present:
  • Airway management: Considering health-care workers have an increased risk of developing COVID-19, especially during high-risk procedures such as intubation, aerosol-generating procedures should be avoided whenever possible! [40][41][42]
    • Endotracheal intubation: Rapid-sequence induction is preferred, especially as it minimizes the spreading of infectious aerosols.
    • To avoid aerosolizing the virus, noninvasive ventilation, high-flow oxygen therapy, bronchoscopy, and nebulizer treatment should be avoided unless there is an absolute indication.
      • If NIPPV is indicated (e.g., COPD, asthma, DNI status): attempt with a helmet (vs. face mask) interface
  • Mechanical breathing: ventilation with lower tidal volumes (LTV) as with ARDS [43]

Medical therapy

  • General information
    • To date, no therapy has proven effective. Any approach is experimental.
    • The use of drugs:[16][45]
      • May be considered in individual cases after weighing the risks and benefits.
      • Is recommended in the context of research studies and compassionate use programs.
  • Potential target structures and agents: A variety of agents are being tested, and clinical studies are being conducted. [46][47]
    • Inhibition of adhesion and invasion
    • Inhibition of fusion
      • Chloroquine or less toxic hydroxychloroquine [48][49][50][51]
        • Hydroxychloroquine In combination with azithromycin is being intensely tested [52]
      • Umifenovir [53]
    • Inhibition of protease
    • RNA polymerase inhibitors and nucleotide analogs
      • Favipiravir [59] (brand name: Avigan®; approved in Japan)
      • Remdesivir [57][58]
      • Baloxavir marboxil
    • Antibody therapy and biologicals [60]
      • Tocilizumab, especially in the phase of ARDS when IL-6 and CRP are increased [61]
      • Recombinant ACE2 (rhACE2, APN01) [15][62]
    • Passive immunization through serum therapy: [63]
      • Immunized individuals (already had COVID-19) donate serum
      • Especially a potential option for risk groups
  • Interactions between the drugs listed: numerous; this must be kept in mind when considering administration (prescribing information!) or use according to information provided by the Liverpool Drug Interaction Group! [64]

The point in time at which a drug is administered during the course of the disease is likely to be a decisive factor. While drugs that inhibit the invasion and replication of the virus (e.g., camostat, rhACE2) would have to be administered as early as possible, other approaches, which aim to control immune response dysregulation in severe courses (e.g., tocilizumab), could also be effective in later stages of the disease!

Discontinuation of isolation and other transmission-based precautions

  • Determining when to end home isolation is approached from different strategies, which can vary according to health departments and testing resources.
  • CDC guidance consists of: [65]
    • For patients with symptomatic COVID-19
      • Non-test-based strategy (time-since-illness-onset and time-since-recovery strategy) consisting of:
        • At least 3 days (72 hours) since recovery, meaning:
          • Resolution of fever without antipyretics AND
          • Respiratory symptoms have improved AND
        • AND at least 7 days since onset of symptoms
      • Test-based strategy (if ample testing resources and convenient access) consisting of:
        • No fever (without antipyretics) AND
        • Respiratory symptoms have improved AND
        • Two negative tests in a row, 24 hours apart
    • For patients with asymptomatic COVID-19: at least 7 days have passed without illness since date of COVID-19 test

Discharging patients from healthcare facility

Recommendations based on CDC guidance: [66]

  • Considered infectious (requirements for discontinuation transmission-based precautions are not met): If clinically indicated, patients may be discharged without meeting criteria for discontinuation of transmission-based precautions.
    • If discharged home: They should follow guidance for home care and isolation as described above in “Management of asymptomatic or mild courses.”
    • If discharged to long-term care or assisted-living facility: Transmission-based precautions should still be followed.
  • Considered noninfectious (requirements for discontinuation transmission-based precautions are met): If clinically indicated, patients may be discharged without COVID-19-associated restrictions.
    • Exceptions: Some patients may have recovered but have persistent symptoms (e.g., cough). Additional precautions are recommended for such individuals (such as wearing a facemask and staying in a single room) until symptoms completely resolve or 14 days after onset of symptoms, whichever is longer.

Prognosis

  • Mortality rate: ranges from ∼ 0.5 to 3%
    • The mortality rate greatly increases for individuals with certain underlying medical conditions or > 60 years of age, with the most lethal rates for individuals > 80 years reaching ∼ 15%. [4]
    • Individuals considered at high-risk for a severe course (and thus a higher mortality rate) include those with: [31]
  • Pediatric patients
    • Most children with COVID-19 experience a mild course and some are asymptomatic. [67][68]
    • A study evaluating 2143 pediatric patients with COVID-19 in China showed: [68]
      • Severe course occurred in 5.9% of cases (vs. 18.5% for adults from the same population study), and only one died.
      • Younger children, especially infants, were more vulnerable to severe or critical course (infants < 11% vs. 7% for ages 1–5 years and less for older pediatric groups).

Although most children with COVID-19 appear to experience a milder course, measures for infection control and prevention should be followed.

Do ACE inhibitors and NSAIDs aggravate COVID-19?

ACE inhibitor and NSAID use as an aggravating factor in COVID-19

Unconfirmed reports and published hypotheses about the pathophysiology of COVID-19 have raised suspicions that RAAS antagonists (esp. ACE inhibitors and angiotensin II receptor blockers), NSAIDs, and thiazolidinediones may facilitate infection with and exacerbate the course of COVID-19.

Fact check

Regardless of COVID-19, NSAIDs may have nephrotoxic and cardiotoxic effects in individuals with cardiovascular and/or renal conditions.

Reliable sources of information

  • Centers for Disease Control and Prevention [1]
  • World Health Organization [2]
  • Johns Hopkins CSSE real-time tracking of COVID-19 spread [69]
  • 1. Coronavirus Disease 2019 (COVID-19). https://www.cdc.gov/coronavirus/2019-ncov/index.html. Updated March 2, 2020. Accessed March 5, 2020.
  • 2. Q&A on coronaviruses (COVID-19). https://www.who.int/news-room/q-a-detail/q-a-coronaviruses. Updated February 23, 2020. Accessed March 5, 2020.
  • 3. Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Coronavirus COVID-19 Global Cases. https://coronavirus.jhu.edu/map.html. Accessed March 28, 2020.
  • 4. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi. 2020; 41(2): pp. 145–151. doi: 10.3760/cma.j.issn.0254-6450.2020.02.003.
  • 5. Guan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020. doi: 10.1056/nejmoa2002032.
  • 6. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8): pp. 727–733. doi: 10.1056/NEJMoa2001017.
  • 7. Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Military Medical Research. 2020; 7(1): p. 11. doi: 10.1186/s40779-020-00240-0.
  • 8. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation and Treatment Coronavirus (COVID-19) [Updated 2020 Mar 8]. url: https://www.ncbi.nlm.nih.gov/pubmed/32150360 Accessed March 22, 2020.
  • 9. Tang X, Wu C, Li X, et al. On the origin and continuing evolution of SARS-CoV-2. National Science Review. 2020. doi: 10.1093/nsr/nwaa036.
  • 10. Hamzelou J. Coronavirus: Are there two strains and is one more deadly?. https://www.newscientist.com/article/2236544-coronavirus-are-there-two-strains-and-is-one-more-deadly/#ixzz6HOqHLBzr. Updated March 14, 2020. Accessed March 22, 2020.
  • 11. Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses. 2020; 12(2). doi: 10.3390/v12020135.
  • 12. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol. 2020; 94(7). doi: 10.1128/JVI.00127-20.
  • 13. Nicholls J, Peiris M. Good ACE, bad ACE do battle in lung injury, SARS. Nat Med. 2005; 11(8): pp. 821–822. doi: 10.1038/nm0805-821.
  • 14. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020. doi: 10.1016/j.cell.2020.02.052.
  • 15. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020. doi: 10.1007/s00134-020-05985-9.
  • 16. Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003; 426(6965): pp. 450–454. doi: 10.1038/nature02145.
  • 17. Yeo C, Kaushal S, Yeo D. Enteric involvement of coronaviruses: is faecal–oral transmission of SARS-CoV-2 possible?. The Lancet Gastroenterology & Hepatology. 2020. doi: 10.1016/s2468-1253(20)30048-0.
  • 18. Linton NM, Kobayashi T, Yang Y, et al. Incubation Period and Other Epidemiological Characteristics of 2019 Novel Coronavirus Infections with Right Truncation: A Statistical Analysis of Publicly Available Case Data. http://dx.doi.org/10.1101/2020.01.26.20018754. Updated January 28, 2020. Accessed March 27, 2020.
  • 19. WHO TEAM Health Emergencies Preparedness and Response. Q&A on coronaviruses (COVID-19). https://www.who.int/news-room/q-a-detail/q-a-coronaviruses. Updated March 9, 2020. Accessed March 27, 2020.
  • 20. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020: p. 101623. doi: 10.1016/j.tmaid.2020.101623.
  • 21. Xu X-W, Wu X-X, Jiang X-G, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020: p. m606. doi: 10.1136/bmj.m606.
  • 22. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11): p. 1061. doi: 10.1001/jama.2020.1585.
  • 23. Prevention & Treatment. https://www.cdc.gov/coronavirus/2019-ncov/about/prevention-treatment.html. Updated February 15, 2020. Accessed March 5, 2020.
  • 24. Frequently Asked Questions about Personal Protective Equipment. https://www.cdc.gov/coronavirus/2019-ncov/hcp/respirator-use-faq.html. Updated February 29, 2020. Accessed March 5, 2020.
  • 25. National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases. Testing for COVID-19. https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/testing.html. Updated March 21, 2020. Accessed March 27, 2020.
  • 26. National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases. Evaluating and Testing Persons for Coronavirus Disease 2019 (COVID-19). https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html. Updated March 14, 2020. Accessed March 27, 2020.
  • 27. Public Health England. Stay at home: guidance for households with possible coronavirus (COVID-19) infection. https://www.gov.uk/government/publications/covid-19-stay-at-home-guidance/stay-at-home-guidance-for-households-with-possible-coronavirus-covid-19-infection. Updated March 24, 2020. Accessed March 27, 2020.
  • 28. Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 (COVID-19). https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html. Updated March 25, 2020. Accessed March 26, 2020.
  • 29. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA. 2020. doi: 10.1001/jama.2020.3786.
  • 30. Information for Health Departments on Reporting a Person Under Investigation (PUI), or Presumptive Positive and Laboratory-Confirmed Cases of COVID-19. https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-home-care.html. Updated March 1, 2020. Accessed March 5, 2020.
  • 31. National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases. People who are at higher risk for severe illness. https://www.cdc.gov/coronavirus/2019-ncov/specific-groups/people-at-higher-risk.html. Updated March 26, 2020. Accessed March 27, 2020.
  • 32. National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases. What To Do if You Are Sick. https://www.cdc.gov/coronavirus/2019-ncov/if-you-are-sick/steps-when-sick.html. Updated March 25, 2020. Accessed March 27, 2020.
  • 33. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020. doi: 10.1016/s0140-6736(20)30566-3.
  • 34. Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus Disease 2019 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients. American Journal of Roentgenology. 2020: pp. 1–7. doi: 10.2214/ajr.20.23034.
  • 35. Qian L, Yu J, Shi H. Severe Acute Respiratory Disease in a Huanan Seafood Market Worker: Images of an Early Casualty. Radiology: Cardiothoracic Imaging. 2020; 2(1): p. e200033. doi: 10.1148/ryct.2020200033.
  • 36. Ai T, Yang Z, Hou H, et al. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology. 2020: p. 200642. doi: 10.1148/radiol.2020200642.
  • 37. Peng Q-Y, Wang X-T, Zhang L-N. Findings of lung ultrasonography of novel corona virus pneumonia during the 2019–2020 epidemic. Intensive Care Med. 2020. doi: 10.1007/s00134-020-05996-6.
  • 38. RSNA Journals - Radiology of Coronavirus: Spectrum of imaging findings. https://pubs.rsna.org/2019-ncov. Accessed March 24, 2020.
  • 39. Wang Y, Dong C, Hu Y, et al. Temporal Changes of CT Findings in 90 Patients with COVID-19 Pneumonia: A Longitudinal Study. Radiology. 2020: p. 200843. doi: 10.1148/radiol.2020200843.
  • 40. Chang D, Xu H, Rebaza A, Sharma L, Dela Cruz CS. Protecting health-care workers from subclinical coronavirus infection. The Lancet Respiratory Medicine. 2020; 8(3): p. e13. doi: 10.1016/s2213-2600(20)30066-7.
  • 41. Cheung JC-H, Ho LT, Cheng JV, Cham EYK, Lam KN. Staff safety during emergency airway management for COVID-19 in Hong Kong. The Lancet Respiratory Medicine. 2020. doi: 10.1016/s2213-2600(20)30084-9.
  • 42. Wax RS, Christian MD. Practical recommendations for critical care and anesthesiology teams caring for novel coronavirus (2019-nCoV) patients. Canadian Journal of Anesthesia/Journal canadien d'anesthésie. 2020. doi: 10.1007/s12630-020-01591-x.
  • 43. Acute Respiratory Distress Syndrome Network, Brower RG, Matthay MA, Morris A, Schoenfeld D, Thompson BT, Wheeler A. Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress Syndrome. N Engl J Med. 2000; 342(18): pp. 1301–1308. doi: 10.1056/nejm200005043421801.
  • 44. NIH-NHLBI ARDS Network. ARDSnet Clinical Network Mechanical Ventilation Protocol Summary. url: http://www.ardsnet.org/files/ventilator_protocol_2008-07.pdf Accessed March 26, 2020.
  • 45. Xie J, Tong Z, Guan X, Du B, Qiu H, Slutsky AS. Critical care crisis and some recommendations during the COVID-19 epidemic in China. Intensive Care Med. 2020. doi: 10.1007/s00134-020-05979-7.
  • 46. Du L, He Y, Zhou Y, Liu S, Zheng B-J, Jiang S. The spike protein of SARS-CoV — a target for vaccine and therapeutic development. Nature Reviews Microbiology. 2009; 7(3): pp. 226–236. doi: 10.1038/nrmicro2090.
  • 47. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Bioscience trends. 2020; 14(1): pp. 69–71. doi: 10.5582/bst.2020.01020.
  • 48. Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases. 2020. doi: 10.1093/cid/ciaa237.
  • 49. Colson P, Rolain J-M, Lagier J-C, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020: p. 105932. doi: 10.1016/j.ijantimicag.2020.105932.
  • 50. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020. doi: 10.1016/j.jcrc.2020.03.005.
  • 51. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery. 2020; 6(1). doi: 10.1038/s41421-020-0156-0.
  • 52. Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020: p. 105949. doi: 10.1016/j.ijantimicag.2020.105949.
  • 53. Xu et al. Clinical Efficacy of Arbidol in Patients with 2019 Novel Coronavirus-Infected Pneumonia: A Retrospective Cohort Study. The Lancet. 2020. url: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3542148.
  • 54. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA. 2020. doi: 10.1001/jama.2020.3204.
  • 55. Chu CM. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004; 59(3): pp. 252–256. doi: 10.1136/thorax.2003.012658.
  • 56. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020. doi: 10.1056/nejmoa2001282.
  • 57. Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nature Communications. 2020; 11(1). doi: 10.1038/s41467-019-13940-6.
  • 58. Agostini ML, Andres EL, Sims AC, et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio. 2018; 9(2). doi: 10.1128/mbio.00221-18.
  • 59. FURUTA Y, KOMENO T, NAKAMURA T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proceedings of the Japan Academy, Series B. 2017; 93(7): pp. 449–463. doi: 10.2183/pjab.93.027.
  • 60. Wang C, Li W, Drabek D, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. http://dx.doi.org/10.1101/2020.03.11.987958. Updated March 12, 2020. Accessed March 23, 2020.
  • 61. Xu X, Han M et al. Preprint: Effective Treatment of Severe COVID-19 Patients with Tocilizumab. url: http://www.chinaxiv.org/abs/202003.00026 Accessed March 16, 2020.
  • 62. Zhang H, Baker A. Recombinant human ACE2: acing out angiotensin II in ARDS therapy. Critical Care. 2017; 21(1). doi: 10.1186/s13054-017-1882-z.
  • 63. Casadevall A, Pirofski L. The convalescent sera option for containing COVID-19. J Clin Invest. 2020. doi: 10.1172/jci138003.
  • 64. University of Liverpool: COVID-19 Drug Interactions. http://www.covid19-druginteractions.org/. Accessed March 23, 2020.
  • 65. National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases. Discontinuation of Home Isolation for Persons with COVID-19 (Interim Guidance). https://www.cdc.gov/coronavirus/2019-ncov/hcp/disposition-in-home-patients.html. Updated March 16, 2020. Accessed March 28, 2020.
  • 66. National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases. Discontinuation of Transmission-Based Precautions and Disposition of Patients with COVID-19 in Healthcare Settings (Interim Guidance). https://www.cdc.gov/coronavirus/2019-ncov/hcp/disposition-hospitalized-patients.html. Updated March 23, 2020. Accessed March 28, 2020.
  • 67. Lu X, Zhang L, Du H, et al. SARS-CoV-2 Infection in Children. N Engl J Med. 2020. doi: 10.1056/nejmc2005073.
  • 68. Dong Y, Mo X, Hu Y, et al. Epidemiological Characteristics of 2143 Pediatric Patients With 2019 Coronavirus Disease in China. Pediatrics. 2020: p. e20200702. doi: 10.1542/peds.2020-0702.
  • 69. Coronavirus COVID-19 Global Cases by Johns Hopkins CSSE. https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6. Updated February 11, 2020. Accessed March 5, 2020.
  • National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Healthcare Quality Promotion (DHQP). Sequence for Donning and Removing Personal Protective Equipment. url: https://www.cdc.gov/hai/pdfs/ppe/ppe-sequence.pdf Accessed March 27, 2020.
  • Centers for Disease Control and Prevention. Interim US Guidance for Risk Assessment and Public Health Management of Persons with Potential Coronavirus Disease 2019 (COVID-19) Exposures: Geographic Risk and Contacts of Laboratory-confirmed Cases. https://www.cdc.gov/coronavirus/2019-ncov/php/risk-assessment.html. Updated March 22, 2020. Accessed March 26, 2020.
  • National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases. Interim Infection Prevention and Control Recommendations for Patients with Suspected or Confirmed Coronavirus Disease 2019 (COVID-19) in Healthcare Settings. https://www.cdc.gov/coronavirus/2019-ncov/infection-control/control-recommendations.html. Updated March 19, 2020. Accessed March 27, 2020.
last updated 03/28/2020
{{uncollapseSections(['ER18Kg0', 'Ki1Usg0', 'ai1QJg0', '6i1jsg0', 'vR1AKg0', 'bi1HJg0', 'CR1q6g0', 'DR116g0', 'wR1h6g0', 'qi1Csg0', 'Ii1YGg0', 'ri1fGg0', '7i14Gg0', '9R1N6g0', 'Yi1nJg0', 'xR1E6g0'])}}